History

2006
Foundation of and start-up financing for Marinomed Biotechnologie GmbH as a spin-off of the University of Veterinary Medicine in Vienna

2007
Development of the Carragelose® platform

2008
Market launch of the first Carragelose® product and equity investment by Acropora

2010
Licensing partnership with Boehringer Ingelheim, initially for 54 countries

2011
Approval in 22 additional countries
Development of an independent sales network with outsourced production and logistics begins

2012–2016
Further product launches and sales partnerships

2016
Development of and feasibility study for the Marinosolv® technology platform

2017 
Change of legal form to a stock corporation
Preparation of a phase III clinical study for the flagship product Budesolv

2018
Certification of a new Carragelose® nasal spray with decongestant properties
Start of phase III clinical study for the flagship product Budesolv

2019
IPO in February, quotation in the prime market segment at Vienna Stock Exchange